Roche
FDA clears Roche eye drug
February 9, 2015Sales and Marketing AMD, DME, FDA, Lucentis, Retina, Roche, eyes, ranibizumab
The US Food and Drug Administration has shown Roche’s eye-condition drug Lucentis the green light to treat patients with diabetic …
Late-stage successes for Amgen and Roche
February 5, 2015Sales and Marketing Amgen, Bendamustine, Gazyva, Genentech, Humira, Levact, Napp, Roche, adalimumab, obinutuzumab
Roche and Amgen have both posted successful late-stage trial results that they say will contribute to their applications for regulatory …
FDA fast-tracks Roche lung cancer drug
February 2, 2015Sales and Marketing Cancer, FDA, MPDL3280A, Roche, bladder, lung, oncology, pdl1
Roche will be celebrating after its investigational cancer drug MPDL3280A has been fast-tracked by the FDA for the second time. …
Government spending on Tamfilu is justified
January 30, 2015Research and Development, Sales and Marketing BMJ, Lancet, Roche, Tamiflu, alltrials, oseltamivir, transparency
The most thorough analysis of Roche’s Tamiflu to date suggests that the controversial treatment can shorten the duration of flu …
Roche oncology sales shine but profits dip
January 29, 2015Sales and Marketing Kadcyla, Perjeta, Roche, avastin, fourth quarter, oncology, q4
Roche has posted a mixed bag of financial results complemented only by strong growth in its oncology and immunology divisions. …
Roche buys French biotech for €470 million
January 19, 2015Sales and Marketing Foundation, Genentech, Orphan, Roche, TRO19622, olesoxime, sma, trophos
Roche is buying France-based biotech Trophos in a deal worth up to €470 million in order to gain access to …
Roche teams up to tackle antibiotics resistance
January 13, 2015Research and Development, Sales and Marketing Antibiotics, Fedora, Meiji, OP0595, Roche, Teixobactin
Roche is to collaborate with Japan-based pharma firm Meiji and Canadian Fedora – two companies specialising in the production of …
Roche stakes $1 billion in cancer gene research firm
January 12, 2015Research and Development, Sales and Marketing Cancer, Foundation Medicine, Genentech, Roche, genomics, jp morgan
Roche has announced a huge billion-dollar investment in the cancer genomics research firm Foundation Medicine. Timed with the beginning of …
Genentech makes $10m gene testing outlay
January 8, 2015Medical Communications, Research and Development, Sales and Marketing 23andME, DNA, Genentech, MHRA, Pfizer, Roche
Genentech has thrown its weight behind the contentious DNA testing company 23andMe, by agreeing a deal to buy the genomic …
Roche dealt with two late-stage blows
December 19, 2014Sales and Marketing Alzheimer's, Alzheimer’s, Cancer, Kadcyla, Perjeta, Roche, Xeloda, trastuzumab emtansine
Swiss giant Roche’s breast cancer treatment Kadcyla has failed to meet its primary endpoint and its investigational Alzheimer’s treatment trial …
Roche adds two to its board
December 18, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bernard Poussot, Richard Lift, Roche, Sanofi
Roche intends to grow at its March annual general meeting via the election of Bernard Poussot and Richard Lift who …
Roche wins drug discovery award for Gazyvaro
December 18, 2014Sales and Marketing BPS, British Pharmacological Society, GSK, Gazyvaro, Roche, mekinist
Roche has been named the winner of the 2015 Drug Discover of the Year award by the British Pharmacological Society …
Big pharma spent $112 billion on R&D in 2013
December 17, 2014Research and Development, Sales and Marketing Merck, Pfizer, R&D, Roche, data, global data, research
The top 30 pharma companies spent a combined total of $112 billion on research and development last year. Calculated to …
Roche submits melanoma drug to FDA
December 15, 2014Sales and Marketing Cobimeinib, FDA, Roche, Zelboraf, mekinist, melanoma, taflinlar, vemurafenib
Roche has submitted its melanoma drug cobimeinib for review with the FDA as it confirms the results of its Phase …
‘Postcode lottery’ still cause of many lung cancer deaths
December 3, 2014Research and Development, Sales and Marketing DoH, Roche, astranzeneca, lung cancer, nlca, oncology, pd-1
Patients are still pointlessly dying of lung cancer due to a ‘postcode lottery’ of services according to new results from …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
